The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113

Authors :: Ikuhiro Yamada
Chigusa Morizane
Takuji Okusaka
Junki Mizusawa
Tomoko Kataoka
Makoto Ueno
Masafumi Ikeda
Naohiro Okano
Akiko Todaka
Satoshi Shimizu
Nobumasa Mizuno
Mitsugu Sekimoto
Kazutoshi Tobimatsu
Hironori Yamaguchi
Tomohiro Nishina
Hirofumi Shirakawa
Yasushi Kojima
Takamasa Oono
Yasuyuki Kawamoto
Masayuki Furukawa
Tomohisa Iwai
Kentaro Sudo
Keiya Okamura
Tatsuya Yamashita
Naoya Kato
Kazuhiko Shioji
Kyouko Shimizu
Toshio Nakagohri
Ken Kamata
Hiroshi Ishii
Junji Furuse
JCOG-HBPOG
Source :: Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Publication Year :: 2022
Publisher :: Nature Portfolio, 2022.
Abstract: Abstract In the FUGA-BT trial (JCOG1113), gemcitabine plus S-1 (GS) showed non-inferiority to gemcitabine plus cisplatin (GC) in overall survival (OS) with good tolerance for patients with advanced biliary tract cancer (BTC). We performed a subgroup analysis focused on the elderly cohort of this trial. All 354 enrolled patients in JCOG1113 were classify into two groups;

Full Text Access

Tools